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Transfus Med Hemother 2011;38: [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] [214] [215] [216] Henseler/Heiden/Haschberger/Hesse/Seitz -State, local authority, non-commercial and private blood donation services at hospitals: Apart from local authority blood donation services, these also include donation facilities at university hospitals and at noncommercial or (in the meantime) privatised hospitals. -Private donation centres: Private donations centres are blood donation services and plasmapheresis centres in the corporate form of a GmbH or AG (public limited company) not operating on a charitable basis and, as a rule, not run by the responsible body of hospitals. -Plasma processing / pharmaceutical companies: This category comprises pharmaceutical enterprises that manufacture, import, or export coagulation factors or other medicinal products from blood plasma as well as recombinant coagulation factor products or sell such products in Germany. -Bundeswehr (German Army): The Army maintains its own blood donation service to provide the soldiers with blood components. Health care organisations which consume blood products are classified as follows: -Clinics and hospitals providing basic, regular, focused or maximum care.
-Panel doctors, dialysis centres, and outpatient clinics.
-Health-care facilities of the German Army.
-'Other medical institutions', comprising rheumatology centres, rehabilitation centres, geriatric, and psychiatric facilities. The above mentioned institutions are required to report the number of blood components transfused, the number of HSC transplanted, and the administration of plasma proteins.
Results and Discussion

Reporting Rates
For 2008, the overall response rate was 81%. 2,300 institutions transmitted their figures in 2009, which is equivalent to around 80% of the institutions registered at the PEI as required to report.
Collection and Manufacture
As in previous years, all blood donation facilities in Germany transmitted their figures. Thus, reliable data are available on the amount of blood components available for transfusion in Germany. Data are missing only on the facilities performing autologous blood collection and on the plasma-processing industry (table 1) .
The number of facilities in which pre-operative autologous blood is donated steadily declined from originally 597 to only 241 facilities in 2009.
Consumption
In 2009, altogether 2,299 reports, corresponding to 80% of the facilities registered at the PEI were received from facilities using blood products. The response rate thus rose by 7% compared with 2007. This means, however, that more than 500 health care facilities still do not report their consumption of blood products (table 2) .
Collection of Blood and Blood Components
In 2008, more than 7.12 million allogeneic blood donations were provided by donors in Germany corresponding to an increase of 7.2% compared with the previous year. The portion
Introduction
The blood donation services, the pharmaceutical industry, and the health care facilities provide the Paul-Ehrlich-Institut (PEI) with annual data on the extent of the collection of blood and blood components, the manufacture, imports, and exports as well as the loss and expiry of blood products and recombinant plasma proteins for the treatment of haemostasis disorders. In the meantime, data are available from the past 10 years. In addition to the documentation of the current supply situation, these data can be used to derive trends on the provision of blood products in Germany. The results are also published on the PEI website [2] in tabular form and updated regularly. The figures published on that website can therefore deviate from the figures provided in this report.
Methodology
Report Forms
Notifications are submitted exclusively by means of a web application, the online reporting system pursuant to Section 21 Transfusionsgesetz (TFG; German Transfusion Act).
Information on the Collection of Blood and Blood Products
This information comprises the number of collections of allogeneic and autologous blood including plasma as the starting material for fractionation as well as haematopoietic stem cells (HSC). Since 2009, the collection of HSC from bone marrow is also recorded here.
Information on the Manufacture, Consumption, Loss and Expiry
This information includes manufacture, imports, exports (including country of origin and country of export), consumption, loss and expiry of blood components, HSC, medicinal products derived from human plasma, and recombinant coagulation factor products.
Information on Patients with Congenital Haemostasis Disorders
Since the reporting year 2008, data on patients with congenital haemostasis disorders requiring treatment pursuant to Section 21 TFG are collected via the German Haemophilia Register (DHR) [3] . This data is still incomplete because the DHR has only been introduced recently. They will be published in the next report. The data include the number of patients with haemophilia A and B categorised by seriousness of the disorder and age group, the number of patients with von Willebrand's disease as well as the total of the products administered to these groups of individuals.
Facilities for Which Reporting Is Compulsory
Manufacturers of blood products and recombinant plasma proteins for the treatment of haemostasis disorders as well as health care facilities consuming blood products are required to report pursuant to Section 21 TFG. Donor facilities are classified as follows: -Blood donation services of the German and the Bavarian Red Crosses:
As a rule, the institutes of the Red Cross operate independently from hospitals. They not only organise blood donations on a large scale but also the provision of the blood components manufactured from these donations. They have the company structure of a non-profit GmbH (limited liability company). Since 2000, the number of preoperative autologous blood collections declined from 216,000 to 48,000 collections in 2009. The portion of autologous blood collections compared with the total number of whole blood donations thus declined from 4.7% to just below 1% (table 4, fig. 1 ). Such a downward trend can also be observed in the member states of the Council of Europe. The current report form 2006 shows a medium portion of autologous blood donations of 0.6% compared with the total of the whole blood donations [5] .
In 2009, 60 whole blood donations were performed per 1,000 inhabitants [8] -a high number compared with that of the member states of the Council of Europe which amounts to a median of 36 whole blood donations per 1,000 inhabitants (quartile distance: 50-24) in 2006 [5] . During the same time of whole blood donations amounted to 68%. In 2009, the German population was even more motivated to donate. More than 7.42 million allogeneic blood donations could be recorded -an increase of 4.2% compared with 2008. The donations were voluntary and gratuitous; expenses associated with blood donations are often compensated conforming to the laws [1, 4] .
Whole blood donations form the basis for the supply with blood products, not only for blood components for transfusion but also for plasma for fractionation as the starting product for the manufacture of medicinal products from human plasma. Hyperimmune plasma from whole blood fig. 1 ). Unlike 2003, the year in which less whole blood donations were collected due to the dramatic increase in apheresis donation, this recent increase has no effect on the number of whole blood donations. Plasmapheresis donations constitute the major portion of apheresis donations; the collection of RBCs and platelets by means of apheresis only accounts for roughly 9% of all apheresis donations. More than 90% of all plasmas collected by means of apheresis are used for the manufacture of plasma proteins.
The effects of the demographic changes on the supply with blood products in Germany are currently being discussed intensively. According to calculations by the Federal Statistical Office, the German population will have declined by up to 15% by 2060 compared with 2008. At the same time, a shift in the age structure will be experienced -the portion of old people in the overall population will rise markedly [7, 8] . Especially in those regions where the age structure is changing drastically, dramatic losses are expected in the supply with blood, while the demand is expected to rise [9] .
In the Federal Republic of Germany as a whole, the number of whole blood donations rose by nearly 12% during the past 10 years although the number of individuals who have reached the minimum age required for donations [20] declined by around 2% [7] . This development can be understood if we take a look at the donor age groups. Thus, the number of 18-to 34-year-olds, the age group with the largest portion of first-time donors, declined by around 9% while the number of 35-to 54-year-olds, who accounted for a large portion of multiple donors, increased by 4% [7] . Donors in this age group play an important part in contributing to the provision of blood components [10] . At the same time, the number of over 65-year-olds, the age group about which it is assumed that they need the largest portion of blood components, rose by 23%.
Intended steps to be taken such as a more liberal regulation of the upper age limit for donors are designed to moderate a possible downward trend. The course of the future development of donor availability remains to be seen. In Germany, the donor frequency can still be described as very high, also compared with our European neighbours where considerably less blood is donated.
RBC Concentrates
Altogether, 4.7 million transfusion units (TU) of RBC concentrates were produced each in 2008 and in 2009 ( fig. 3) . The major portion of these RBC concentrates originates from whole blood donations, while only 0.4% was produced from apheresis donations (table 3) . With a portion of 72% of the RBC concentrates manufactured, the institutes of the German and Bavarian Red Cross continued to be the major man- Since 2004, the PEI also records the manufacture of irradiated RBC concentrates. The portion of these RBC concentrates compared with the over-all amount of RBC concentrates has risen from 3.2 to 4.0%.
The already low number of RBCs from autologous blood donations, continued to decline. The rate for RBCs from autologous donations compared with the total supply of RBCs ufacturers, followed by the group of state, local authority, and other non-profit donor organisations as well as the facilities of private hospital operators with an unchanged portion of 20% over several years. The portion of private donor services rose continuously from 2.2% in 2000 to currently 7.5%. The portion of RBC concentrates provided by the German Army for general use has remained constant with around 0.7%. if they constitute released products, there is a lower limit of the expiry rate which cannot be exceeded. The latter has obviously been reached in the meantime.
Due to missing reports on the use of blood products from health care facilities, the approximate number of RBCs transfused was estimated on the basis of the products delivered by the donor services and the expiry figures reported by the users [11] . Based on this information, around 4.5 million RBC concentrates were transfused in 2008 and 2009, to an increasing extent also in an out-patient setting in panel doctor's practices and day clinics. While the portion of transfusions of RBC concentrates in these facilities was 4.6% in 2004, it rose to 7.9% in 2009.
Since no reports on expiry figures were available from a part of the facilities performing RBC transfusions, the portion decreased from 3.3% in 2000 to 0.7% in 2009. With 44%, the portion of expired autologous RBCs is markedly above that of allogeneic products. An even larger expiry rate was recorded for whole blood for transfusion from autologous blood donations -almost 60% in 2009.
In 2008 and 2009, 978 and 977 RBC concentrates respectively were manufactured per 1,000 whole blood donations. Thus the best yield in the past 10 years could be obtained in 2008 with a loss before release of only 2.2%.
The expiry rate of released RBCs in the donation services, too, continues to decrease and was below the level of previous years in 2009 with 1.36% (fig. 4) . It has become clear that manufacturers have made major efforts to minimise the expiry rate for their products. Since the products required for quality and sterility controls must also be recorded as expiry, Henseler/Heiden/Haschberger/Hesse/Seitz
The supply level of RBC concentrates for the German population can still be considered as good, with 58 per 1,000 inhabitants, above all compared with the member states of the Council of Europe. The median of these countries was 36 RBC concentrates per 1,000 inhabitants in 2006 (quartile distance: 48-29). The figure of 2006 in Germany was 55 [5] . Detailed studies of the supply of RBC concentrates have shown that the supply can fluctuate by up to 20% during one given of RBC concentrates expired at the user was calculated in two ways: it was calculated i) in comparison with the total of RBC concentrates reported as transfused in assuming that the facilities that did not report any expiry figures in fact did not have any expiry (reported expiry rate) and ii) taking into account only the number of RBC concentrates reported by those facilities that had simultaneously reported expiry (corrected expiry rate) ( fig. 4) . The portions accounted for by the different types of manufacture have remained unchanged. Around 60% of the platelet concentrates are manufactured by means of apheresis. One apheresis procedure produces 1.8 platelet concentrates on average. Pooled platelet concentrates are manufactured from year [12] . Health care facilities are obviously able to overcome temporary bottle necks in the supply by prioritising and appropriate planning.
Platelet Concentrates
The favourable trend for the manufacturing figures of platelet concentrates continued in 2009, with 520,000 platelet concen- platelet concentrates. While the expiry rate for apheresis platelet concentrates moderately increased again after its low of 3% in 2007, with 1% per annum, it increased for pooled platelet concentrates from below 12 to 17%. The reason for the increase in the expiry rate -above all for pooled platelet concentrates -could be explained by the fact that a cut in the shelf life of 1 day was recommended in Opinion 38 in 2008 around 18% of the whole blood donations (table 3, [13] together with a possibly stagnating demand for these products (table 3, fig. 6 ). Apheresis platelet concentrates are supplied in a highly demand-orientated manner so that accordingly, almost all these products are transfused. Compared with this, an increased quantity of pooled platelet concentrates has obviously been manufactured for stock-piling purposes to balance out any possible bottlenecks caused by the cut in the shelf-life, which, however, could not be transfused due to lack of demand and expired as a consequence. In 2009, for the first time after 6 years, fewer products were transfused compared with the previous year (table 3). Whether or not this high expiry rate will again decrease in the next few years, thanks to the change in manufacturing management and distribution logistics, remains to be seen.
Plasma for Transfusion
After 2007 when the largest therapeutic plasma quantity of the last 7 years was manufactured, the manufacture decreased again to 1.1 million units in 2009 (table 3, fig. 7 ). In 2009, a graduated plan came into force designed to reduce the risk of transfusion-related acute lung injury (TRALI). This graduated plan bans the marketing of untested plasma of women with a history of pregnancy [14] . There was no risk of a bottleneck, since, among other things, shortages can be mitigated by targeted plasmapheresis from male donors. Figures provide proof that no bottlenecks occurred after the graduated plan relating to TRALI was implemented. Amazingly enough, with 23%, the portion of plasma for transfusion manufactured from apheresis even dropped to its lowest level so far observed. The quantity of plasma produced from whole blood rose both for therapeutic plasma and for plasma for fractionation. At the same time, the quantity of plasma for fractionation produced from plasmapheresis also increased (fig 7 and 9) .
Thanks to the long shelf-life of therapeutic plasma, the expiry rate is lower than for the more perishable cellular blood components. From 2000 to 2009, the mean expiry rate at the manufacturers was 1.6% with a markedly lower expiry rate reported for 2009 amounting to only 0.6%. The mean expiry rate at the users was 3.0% of the quantity distributed for transfusion purposes. Expiry of SD plasma at the users was clearly below that figure with a mean rate of 1.1%.
An indicator in the reports of the Council of Europe for the national use of blood component is the ratio of the plasma units transfused over the RBCs transfused (plasma/RBC ratio). According to these reports, between 2001 and 2006 the mean for Europe was one TU plasma per 2.5 RBC concentrates (plasma/RBC ratio = 0.39). In Germany, the ratio was below the mean for Europe throughout this period with values between 3.7 and 2.9 transfused RBC concentrates per plasma unit (plasma/RBC ratio 0.27-0.34). Whereas the ratio calculated for Germany has decreased markedly in the past 10 years, no general trend could be observed for Europe. This statement is based on the plasma/RBC ratio calculated from Henseler/Heiden/Haschberger/Hesse/Seitz
Plasma for Fractionation
The collection of plasma as a starting material for the manufacture of plasma proteins continued to increase in Germany.
For the first time in 2008, the 2.5 million l limit was reachedequivalent to an increase of 12% compared with the previous year. A further increase in the quantity of plasma for fractionation by 16% to 2.9 million l could be recorded in 2009; 58% of this quantity originates from plasmapheresis (table 5, fig. 9 ). The total quantity collected is equivalent to 35.5 l per 1,000 inhabitants. In the member states of the Council of Europe, the median collection in 2006 was 5 l (quartile distance 14-2) per 1,000 inhabitants; the figure for Germany was 26 l for the same year [5] . These increases are almost entirely brought about by private plasmapheresis centres. These facilities were able to more than double their production since 2005. In addition, the donation services of the Red Cross were able to step up their collection of plasma for fractionation by 17%, while the collection levels accounted for by state, local authority, and other non-profit-making donor services together with the facilities of private hospital operators and the German Army more or less remained at the level of 2007. Private plasmapheresis centres by now contribute 61% to the total quantity collected. 33% are contributed by the Red Cross and 6% by other donor services ( fig. 10) .
Germany is the number one supplier of plasma for fractionation in Europe. In 2006, around 50% of the stock reported from Europe was produced in Germany [5] . Reported figures from the past 2 years show the very complexity of international trade with this raw material, indicating the total of all units reported as transfused in a given country ( fig. 8) .
If, however, the consumption by university and traumatology hospitals, which care for trauma patients with massive bleeding, is compared with that of 'other' health care facilities and hospitals in general, a dramatic difference is observed. Conforming to the recommendations of the cross section guidelines for the treatment with blood components and plasma derivatives [15] , the pro rata plasma consumption has decreased in the major part of the 'other' facilities from one TU plasma per approximately 3.7 RBC concentrates in 2000 (plasma/RBC ratio = 0.27) to one TU plasma per 5.3 RBC concentrates in 2009 (plasma/RBC ratio = 0.19). The ratio at university and accident hospitals has remained nearly unchanged ever since 2001 with on average one TU plasma transfused per 1.8 RBC concentrates (plasma/RBC ratio = 0.55). This shows that a restrictive use of plasma in the treatment of excessive bleeding is obviously considered not to be appropriate. This phenomenon is also highlighted by studies of patients with massive transfusion requirements. Here, a lower mortality rate was observed if the plasma/RBC ratio for the transfusion was 0.6 [16] . Current recommendations from traumatologists on the portion of plasma in massive transfusions are in line with these observations [17] . The difference in plasma/RBC ratios between the group comprising university and traumatology hospitals and that comprising all other health care facilities performing transfusions is significant for all the years observed (Mann-Whitney U test p < 0.05). Here, it becomes apparent that an undifferentiated consideration of the plasma/RBC ratio disregards important facts ( fig. 8) . In the subsequent years, the portion of plasma fractionated in Germany decreased to 61% (table 5, fig. 11 ). Arithmetically, there is a remainder of 1 million l for 2009 for which no explanation can be made. Such residual quantities could also be observed in previous years [11] . The quantity totalled as from 2004 suggests that there should be stocks in Germany of 2.5 million l.
that the quantities of imported and exported plasma for fractionation produced in Germany were approximately equivalent. The net quantity available on the German market amounted to around 2.3 million l in 2008 and 2.6 million l in 2009 equivalent to around 91% of the quantity produced in Germany. In 2007, the net quantity available in Germany was almost entirely used for further processing in Germany. Henseler/Heiden/Haschberger/Hesse/Seitz The products are manufactured by less than three pharmaceutical companies. Therefore they are not published.
c Data is still incomplete. They will be published in the next report. (table 6) .
Haematopoietic Stem Cells
The number of stem cell preparations manufactured in Germany amounts to roughly 25,000 transplantation units (TXU).
Plasma Proteins
In Germany, there is still no shortage of plasma proteins. Although plasma is available as starting material in large quantities, some products are not manufactured in Germany; however, the demand is satisfied thanks to the import of these products. In this context, the supply is rather greater than the demand for a major part of these products. The median per- Henseler/Heiden/Haschberger/Hesse/Seitz 40%for allogeneic products. More than 50% of the manufactured allogeneic stem cell products were exported. Based on the assumption that these products, too, were 100% transplanted, the transplantation rate has risen to even 96%. These figures show that the greatest significance is currently attached to the transplantation of haematopoietic stem cells from peripheral blood (table 7) . Germany is increasingly becoming an exporter for allogeneic stem cell transplants. In 2003, the portion exported was still 21%, while in 2009, 35% of the products manufactured were exported. The portion of imported transplants, on the other hand, is negligible ( fig. 12, 13 ).
